3,638 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Purchased by Osmosis Investment Management UK Ltd

Osmosis Investment Management UK Ltd bought a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 2nd quarter, HoldingsChannel.com reports. The fund bought 3,638 shares of the biopharmaceutical company’s stock, valued at approximately $1,095,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Daiwa Securities Group Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 0.3% in the 2nd quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock valued at $4,220,000 after buying an additional 35 shares during the period. Golden State Wealth Management LLC lifted its stake in Alnylam Pharmaceuticals by 100.0% during the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 36 shares during the last quarter. Coldstream Capital Management Inc. lifted its stake in Alnylam Pharmaceuticals by 2.4% during the third quarter. Coldstream Capital Management Inc. now owns 1,640 shares of the biopharmaceutical company’s stock worth $748,000 after purchasing an additional 38 shares during the last quarter. Atlantic Union Bankshares Corp boosted its holdings in Alnylam Pharmaceuticals by 20.9% in the fourth quarter. Atlantic Union Bankshares Corp now owns 231 shares of the biopharmaceutical company’s stock valued at $92,000 after purchasing an additional 40 shares in the last quarter. Finally, Laird Norton Wetherby Wealth Management LLC boosted its holdings in Alnylam Pharmaceuticals by 3.3% in the third quarter. Laird Norton Wetherby Wealth Management LLC now owns 1,266 shares of the biopharmaceutical company’s stock valued at $577,000 after purchasing an additional 40 shares in the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on ALNY shares. Bank of America cut their price objective on shares of Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating on the stock in a report on Tuesday, July 14th. HC Wainwright lowered their target price on shares of Alnylam Pharmaceuticals from $485.00 to $455.00 and set a “buy” rating for the company in a report on Friday, July 31st. Wall Street Zen downgraded shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 2nd. Royal Bank Of Canada cut their price target on shares of Alnylam Pharmaceuticals from $445.00 to $350.00 and set an “outperform” rating on the stock in a research note on Friday, July 31st. Finally, Raymond James Financial raised shares of Alnylam Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a $420.00 price target for the company in a research report on Monday, August 3rd. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $386.62.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of the firm’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the transaction, the director directly owned 1,582 shares of the company’s stock, valued at approximately $473,302.76. This trade represents a 70.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY opened at $236.01 on Tuesday. The stock has a market cap of $31.58 billion, a P/E ratio of 43.87 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a twelve month low of $197.81 and a twelve month high of $495.55. The stock has a 50 day moving average of $265.98 and a two-hundred day moving average of $296.21. The company has a current ratio of 3.05, a quick ratio of 2.99 and a debt-to-equity ratio of 0.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.63 by $0.21. The business had revenue of $1.29 billion for the quarter, compared to analyst estimates of $1.32 billion. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The company’s revenue for the quarter was up 66.9% compared to the same quarter last year. During the same period last year, the firm posted ($0.51) earnings per share. On average, research analysts forecast that Alnylam Pharmaceuticals, Inc. will post 6.59 earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.